January 29, 2021—This ISHNE/HRS/EHRA/APHRS collaborative statement describes the current status of mobile health (mHealth) technologies in arrhythmia management. The range of digital medical tools and heart rhythm disorders that they may be applied to and clinical decisions that may be enabled are discussed. The facilitation of comorbidity and lifestyle management (increasingly recognized to play a role in heart rhythm disorders) and patient self-management are novel aspects of mHealth. The promises of predictive analytics but also operational challenges in embedding mHealth into routine clinical care are explored.
The aim of this document is to define state-of-the-art mHealth technologies and their application in arrhythmia management and explore future directions for clinical application. As such, the scope of the document encompasses discussion of the different mHealth technologies currently available or in development; the acquisition of health-related data; the applications of such data, including disease identification and management; clinical trials; the patient perspective; and the issues that must be addressed in the future to permit useful application of mHealth technologies. Additionally, discussion is extended to mHealth facilitation of those comorbidities increasingly recognized to influence arrhythmia management (e.g., obesity and sleep apnea) that are becoming the responsibility of heart rhythm professionals.

The Russian and Spanish (Executive Summary) translations are available.
Topic
- Atrial Fibrillation
- Clinical EP
- Clinical Topics
Resource Type
- Clinical Guidelines
Related Resources
Clinical Guidelines
2026 HRS/AHA/APHRS/EHRA/IDSA/LAHRS/PACES/STS Expert Consensus Statement Update on Cardiovascular Implantable Electronic Device Lead Management and Extraction
April 23, 2026
Clinical Guidelines
2025 SCAI/HRS Clinical Practice Guidelines on Transcatheter Left Atrial Appendage Occlusion
August 4, 2025
Clinical Guidelines
2024 HRS Expert Consensus Statement on Arrhythmias in the Athlete: Evaluation, Treatment, and Return to Play
May 17, 2024